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Robust and accurate detection and 
sizing of repeats within the DMPK 
gene using a novel tp-pCR test
Maike Leferink1, Daphne p. W. Wong2, shiwei Cai2, Minli Yeo2, Jocelin Ho2, Mulias Lian3,  
erik-Jan Kamsteeg1, samuel s. Chong3,4,5, Lonneke Haer-Wigman1 & Ming Guan2
Myotonic dystrophy type 1 is a multisystem disorder caused by the expansion of a trinucleotide repeat 
in the DMPK gene. In this study we evaluated the performance of the FastDM1tM DMPK sizing kit in 
myotonic dystrophy type 1 testing. This commercially available triplet repeat-primed PCR based kit 
was validated using reference and clinical samples. Based on testing with 19 reference samples, the 
assay yielded repeat sizes within three repeats from the consensus reference length, demonstrating 
an accuracy of 100%. Additionally, the assay generated consistent repeat size information with a 
concentration range of template-DNA, and upon repetition and reproduction (CV 0.36% to 0.41%). 
Clinical performance was established with 235 archived prenatal and postnatal clinical samples, yielding 
results of 100% sensitivity (95% CI, 97.29% to 100%) and 100% specificity (95% CI, 96.19% to 100%) in 
classifying the samples into the respective genotype groups of 5–35 (normal), 36–50 (non-pathogenic 
pre-expansion), 51–150 (unstable intermediate-sized pathogenic) or >150 (unstable pathogenic) CTG 
repeats, respectively. Furthermore, the assay identified interrupted repeat expansions in all samples 
known to have interruptions, and also identified interruptions in a subset of the clinical samples.
Myotonic dystrophy type 1 (DM1; MIM#160900) is a multisystem disorder caused by abnormal expan-
sion of a CTG repeat in the 3′ untranslated region of the dystrophia myotonica-protein kinase gene (DMPK; 
MIM*605377)1–3. The size of the abnormal expansion in affected individuals has a positive association with the 
severity of symptoms and an inverse correlation with age of disease onset4. The disorder is autosomal dominantly 
inherited and affects multiple systems including skeletal and smooth muscle, as well as eyes, heart, endocrine and 
central nervous system5. Upon transmission to offspring the repeat length may increase and lead to a more severe 
disease, a mechanism known as anticipation. The broad spectrum of clinical presentations of DM1 overlap exten-
sively with those of other disorders; and molecular testing is essential for a definitive diagnosis6.
Existing EMQN (European Molecular Genetics Quality Network) best practice guidelines classify the DMPK 
CTG repeats into four size ranges based on repeat stability and disease phenotype7. (1) Range of 5 to 35 repeats 
(CTG(5–35)) as stable repeats present in healthy individuals with no DM1 phenotype (normal alleles). (2) Range 
of 36 to 50 repeats (CTG(36–50)) as repeats at risk of instability on transmission present in healthy individuals 
(non-pathogenic pre-expansion alleles). (3) Range of 51 to 150 repeats (CTG(51–150)) as unstable repeats pres-
ent in individuals who are either asymptomatic or have minimal or classical DM1 (unstable intermediate-sized 
pathogenic alleles). (4) Range of more than 150 repeats (CTG(>150)) as unstable repeats associated with more 
severe forms of classical, juvenile or congenital DM1 (unstable pathogenic alleles). Consequently, the sizes of 
CTG repeats are critical parameters for clinical diagnosis, even though the boundaries in repeat lengths of the 
four groups should not be interpreted too rigidly due to the existence of a large inter-individual variability7,8.
Traditionally, the detection of CTG expansions included two tests i.e. standard PCR followed by fragment 
length analysis and Southern blot analysis7. The standard PCR technique, although sufficient in detecting the 
lower range of CTG expansions, is not reliable in amplifying repeats of over ~150 CTG repeats) and may fail 
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to detect larger expansions when smaller alleles are preferentially amplified (allelic dropout)6. Therefore, sam-
ples in which only one repeat length is detected by PCR must be further analyzed for the possible presence 
of an expanded allele7. Southern blot analysis has been the gold standard for expanded allele detection, but is 
notoriously laborious, expensive and requires large amounts of DNA (in case of genomic DNA Southern blot) 
and has functional limitations in identifying interrupted alleles (in case of long-range PCR Southern blot). It is 
not surprising that this method has been replaced by alternative approaches such as triplet-repeat primed PCR 
(TP-PCR) in most diagnostic centers7.
Various TP-PCR based approaches have been developed and TP-PCR has proven to be an accurate technique 
in DM1 expansion analysis7,9–11. In the TP-PCR technology, (CAG)n or (CTG)n primers are used for the ampli-
fication of the repeat. These primers bind randomly to the repeat, and, in combination with a primer outside the 
repeat followed by PCR, will result in a pool of DNA fragments (Supplementary Fig. S1). Size separation of these 
fragments results in the specific ‘ladder’ or ‘comb-tooth’ pattern (Supplementary Fig. S1). This pattern is weaker 
in the longer repeat range and will quench due to technical issues, rather than that the end of the repeat expansion 
is reached. Consequently, many laboratory-derived assays fail to distinguish between the diagnostically important 
difference of the higher end intermediate pathogenic (CTG(51–150)) and large pathogenic (CTG(>150)) alleles, due to 
an extinction of the TP-PCR signal before 150 CTG’s are reached.
In 3–5% of the population the normally pure CTG repeat is interrupted by other repeat sequences, such as 
CCG or CGG repeats12–14. These repeat-interruptions may have effect on the melting and subsequent amplifica-
tion of the template DNA (often the interruptions are CCG or CGG, increasing the CG-content). Additionally, 
the (CAG)n or (CTG)n repeat primers cannot bind to the interruption, thereby the quenching of the signal can 
be missed. Alleles with such interruption are thus prone to remain undetected or to be inaccurately sized15. The 
aim of the current study is to validate a commercial kit based on the bidirectional TP-PCR approach on its perfor-
mance and utility in diagnostic DM1 testing.
Results
sizing accuracy. The accuracy of the FastDM1TM DMPK sizing kit was evaluated using 19 reference samples, 
covering the range of normal to unstable expanded alleles (Supplementary Table S1). For ten reference samples 
a consensus length was determined by three independent laboratories and the other nine were verified by one 
laboratory16. All repeat lengths determined by the DMPK sizing kit were within three repeats to the (consensus) 
repeat lengths of the study by Kalman et al.16. (Supplementary Table S1). In conclusion, a total agreement of 100% 
in sizing between the test results and the expected result was reached. It should be noted that a sizing cut-off of 
180 repeats was used following the DMPK sizing kit manufacturer’s instructions. Consequently, alleles with repeat 
sizes equal to or beyond 180 repeats were all reported as having >180 repeats and considered to be in agreement 
with the expected results regardless of their exact sizes.
Analytical sensitivity. The analytical sensitivity of the DMPK sizing kit was evaluated using four reference 
samples by examining the accuracy of the sizing results using varying amounts of DNA inputs of 1, 5, 10, 25, 50 
and 200 ng. A reduction to 25 ng or increase to 200 ng of DNA input elicited no change on the detection or sizing 
accuracy for all alleles ranging from normal to unstable pathogenic repeats (Supplementary Table S2). A reduc-
tion to 10 ng or less DNA input elicited no change on the detection or sizing accuracy for all alleles except for the 
unstable intermediate-sized pathogenic allele in NA23378 in which the determined repeat length deviated with 5 
or 6 repeats compared to the expected repeat length in either or both the 5′ and 3′ reactions.
Detection of simulated mosaic samples. The analytic sensitivity and accuracy of the DMPK sizing kit in 
detecting mosaicism was evaluated using four series of simulated mosaic mixtures derived from eight reference 
samples with repeat sizes of 79, 475, ~1000 and ~1600 of the repeat expansion respectively. A mosaic level of 2.5% 
could be detected by both the 5′ and 3′ reactions, at 1% mosaicism the repeat expansion was missed by the 5′ reac-
tion in case A (Supplementary Table S3). However, in the low mosaic range the sizing of the repeat expansion was 
not accurate. At a mosaic level of 10% or less, correct sizing of the repeat expansions was compromised by either 
the 5′ or 3′ reaction, or both. This indicates that mosaic samples can be reliably detected using the DMPK sizing 
kit, but that the repeat size can be underestimated at low (10% or less) levels of mosaicism.
Analytical specificity. The analytical specificity of the DMPK sizing kit was in theory based on the dis-
tinctiveness of the primer sets designed for the test. Nevertheless, this aspect was additionally tested following a 
similar approach reported in a previous study17, using a DNA sample with a 58–65 CTG expansion in the unre-
lated TCF4 gene. This TCF4 gene CTG repeat did not influence the TP-PCR primers as two normal alleles of 10 
and 13 CTG repeats in the DMPK gene were detected (Supplementary Fig. S2). Furthermore, the TCF4 reference 
sample was added to each of four DMPK reference samples used in the sensitivity study and also in these samples 
the DMPK CTG repeat profiles were not altered by the TCF4 expansion (Supplementary Table S4). These results 
demonstrated that the DMPK sizing kit can accurately size and genotype the DMPK alleles in the presence of 
other non-DMPK CTG repeats.
Consistency. The study of consistency included intra-assay consistency, and intra- and inter-batch reproduc-
ibility. All consistency studies were conducted using four reference samples covering the respective genotypes of 
CTG(5–35), CTG(51–150) and CTG(>150). For the intra-assay consistency, each sample was tested in ten replicates for 
each of the 5′ and the 3′ reactions, after which amplicons were subjected to two runs of capillary electrophoresis. 
Consequently, a total of 40 data points were obtained for each DNA sample tested. For intra-batch reproducibil-
ity, three kits: the first, middle and final kit; from a single production assembly process were sampled. Each kit 
was tested using both the 5′ and the 3′ reactions in at least twelve replicates. Finally, inter-batch reproducibility 
was determined using kits from three batches of production over a period of two years. The data set consisted of 
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test results obtained by different operators using the same samples tested in duplicates or triplicates. The assay 
produced no variations in sizing for all alleles with repeat length less than 100. The variations observed were from 
the larger alleles of >100 repeats of sample NA23378 but with the respective coefficient of variations (CV) of no 
greater than 0.41% (Supplementary Table S5). Because the assay reports all alleles with triplet repeats more than 
180 as >180 repeats, the CV calculation was not applicable for the large allele of NA04567 in the study.
performance on clinical samples. The clinical performance of the DMPK sizing kit was examined using 
225 postnatal and 10 prenatal clinical samples. The samples were previously characterised for DMPK CTG repeat 
length using a combination of methods including conventional PCR, TP-PCR and/or Southern blot of long-range 
PCR products. Firstly, the kit correctly sized 100% of the alleles in CTG(5–35);CTG(5–35) genotype samples (194/194 
alleles in 94 postnatal and 3 prenatal cases) and 100% of the alleles in CTG(5–35);CTG(36–50) genotype samples 
(40/40 alleles in 20 postnatal cases) within 1 repeat of the reference results (Table 1). Secondly, 100% of the nor-
mal alleles and 44 unstable intermediate-sized pathogenic alleles in a total of 49 CTG(5–35);CTG(51–150) genotype 
samples (all postnatal) were sized within 5 repeats of the references (Table 1). The five unstable intermediate-sized 
pathogenic alleles that deviated by more than 5 repeats compared to the reference, USN31820, USN05133, 
USN16457, USN16779 and USN04608 (all postnatal samples), were originally sized as borderline alleles with 
repeats sizes approaching 150 repeats (more specifically 135, 140, 147, 149 and 140, respectively) while the DMPK 
sizing kit determined expansions of >180 repeats. To verify the correct repeat length in all five discrepant sam-
ples, they were additionally tested using Southern blot and were determined to have expanded alleles in the range 
of >180 repeats and relocated to CTG(>150) for overall analysis (Table 2). Lastly, 68 normal alleles in a total of 69 
CTG(5–35);CTG(>150) genotype samples (63 postnatal and 6 prenatal) were sized to within 1 repeat of the reference 
and all unstable alleles were determined to have a repeat length >150 (Table 1). One normal allele was misinter-
preted to have 5 CTG repeats instead of 34. In this case (USN16349) the signal of the 34 repeat allele was masked 
by the expansion on the other allele (Fig. 1). In summary, the total agreement on sizing accuracy between the kit 
and the references were 99.7% (331/332 alleles) within 1 repeat for the normal alleles (<35 repeats) and 96.38% 
(133/138 alleles) within the same genotype group for the pre-expansion and unstable alleles (>35 repeats).
Nonetheless, the DMPK sizing kit correctly classified all the 235 clinical samples into their respective gen-
otypes as [CTG(5–35); CTG(5–35)] (n = 97), [CTG(5–35)/CTG(36–50)] (n = 20), [CTG(5–35)/CTG(51–150)] (n = 44) and 
[CTG(5–35)/CTG(>150)] (n = 74) (Table 2). Collectively, the overall findings indicate an overall performance of the 
kit in detecting the CTG expansions as having 100% clinical specificity and sensitivity (95% CI: 96.19% to 100% 
Genotype
Sample 
size
Repeat Size Concordance
Allele 5–35rpts Allele ≥36rpts
Within 1 repeat (±1) Within 1 repeat (±1) Within 5 repeats (±5) Within same genotype group
CTG(5–35); CTG(5–35) 97 194/194 — — —
CTG (5–35); CTG (36–50) 20 20/20 20/20 20/20 20/20
CTG (5–35); CTG (51–150) 49 49/49 31/49 44/49 44/49
CTG (5–35); CTG (>150) 69 68/69* N.A.† N.A.† 69/69
Total Agreement 331/332 (99.70%) 51/69 (73.91%) 64/69 (92.75%) 133/138 (96.38%)
Table 1. Repeat size concordance of clinical samples using the DMPK sizing kit in comparison with the in-
house methods at Radboud University Nijmegen Medical Center7. N.A. not applicable. *In one CTG (5–35); CTG 
(51–150) genotype sample, the peak pattern of the 34 CTG normal allele was masked by the larger allele and was 
misinterpreted as carrying 5 CTG repeats. †In all CTG (5–35); CTG (>150) genotype samples the exact length of the 
allele >150 rpts could not be determined in the reference test and DMPK sizing kit.
Classification based on the reference methods at Radboud 
University Nijmegen Medical Center
Normal Expanded
CTG (5–35)
CTG 
(36–50)
CTG 
(51–150) CTG (>150)
Classification using 
the commercial 
DMPK sizing kit
Normal CTG (5–35) 97TN 0FN 0FN 0FN
Negative Predictive 
Value = 97/97 100%
Expanded
CTG (36–50) 0FP 20TP 0FN 0FN
Positive Predictive 
Value = 138/138 100%CTG (51–150) 0
FP 0FP 44TP 0FN
CTG (>150) 0FP 0FP 0FP 69 + 5TP*
Clinical Specificity = 97/97 
100% (95% CI: 96.19–100%)
Clinical Sensitivity = 138/138 
100% (95% CI: 97.29–100%)
Table 2. Classification of clinical samples using the DMPK sizing kit in comparison with the in-house methods 
at Radboud University Nijmegen Medical Center7. TN: True Negative; FN: False Negative; TP: True Positive; FP: 
False Positive. *The five samples were originally sized under the CTG(51–150) genotype, but relocated into the 
CTG(>150) genotype upon additional Southern blot testing.
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for specificity; 97.29% to 100% for sensitivity, respectively). The results also demonstrated the utility of the kit 
with 100% in positive predictive value (PPV) and negative predictive value (NPV) respectively (Table 2).
Detection of CtG Repeats with interruptions in clinical samples. Repeat-interruptions of the nor-
mally pure CTG repeat influence DNA melting, but more importantly, will not be a template for the (CAG)n or 
(CTG)n primers used in the TP-PCR techniques. To test whether repeats with interruptions are detected by the 
DMPK sizing kit, eight samples with previously observed interruptions were tested. In six samples the electro-
pherogram patterns showed regions with gaps, indicative of the interruptions (Fig. 2). Although, USN03117 and 
USN01084 had continuous patterns in the electropherograms, the result of the DMPK sizing kit deviated from the 
non-interrupted repeat samples as in these samples the repeat length of the largest allele differed by 100 and 16 
repeats between the 5′ and 3′ reactions, respectively (Table 3). Moreover, in the other six samples the repeat length 
determined by the 5′ and 3′ reactions also differed by more than 5 repeats (range 8–111; Table 3).
Additionally, in 16 of the 235 clinical samples repeat interruption’s were detected by the DMPK sizing kit. 
These were detected in seven samples with normal alleles (CTG(5–35)) and nine samples with an unstable path-
ogenic allele (CTG(>150)). In all seven interrupted CTG(36–50) samples, interruptions were detected by both 5′ 
and 3′ reactions. Of note, based on sample (USN12581) that was additionally verified by Sanger sequencing to 
have (CTG)6(CCGCTG)14(CTG)5, the 5′ reaction of the kit correctly detected the exact interruption with the 
flanking CTG repeats (Supplementary Table S6). In contrast, in seven out of nine samples with an interrupted 
CTG(>150) allele gaps were only present in the pattern of either the 5′ or 3′ reaction (Supplementary Table S6). In 
all interrupted CTG(>150) alleles the repeat length of the largest allele determined by the 5′ and 3′ reactions devi-
ated by more than 5 repeats, while there was no difference in repeat length in the interrupted CTG(5–35) samples 
(Supplementary Table S6). In conclusion, the sizing kit is able to detect interrupted repeats in the DMPK gene, 
although sizing of alleles with interruptions may be less accurate.
Discussion
The accuracy in sizing the CTG repeats is undeniably a critical parameter in DM1 testing even though the bound-
aries in repeat lengths should not be taken too rigidly predicting disease onset or severity7. For all 19 reference 
samples (39 alleles; due to ‘mosaicism’ in one patient having one normal allele (12 repeats) and two distinct pop-
ulation of repeat expansion of 56 and 70 repeats, Supplementary Table S1), detected repeat lengths where within 
3 repeats to the (consensus) repeat length determined in the study by Kalman et al.16, reaching an accuracy of 
100%. Next, the analytical sensitivity, analytical specificity and consistency of the DMPK sizing kit were assessed. 
Firstly, the length of the CTG repeat could be correctly identified using a DNA input of 25 to 200 ng. Furthermore, 
a mosaic level of up to 1% was identified by either the 5′ or 3′ reaction, whereas correct sizing of the repeat length 
was compromised below 20% mosaicism only. Secondly, a sample with 58–65 CTG repeats in the TCF4 gene did 
not interfere with the DMPK sizing result. Thirdly, the consistency of the DMPK kit was established to have a 
coefficient of variation of <0.41% for intra-assay, intra-batch or inter-batch variations.
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Figure 1. Electropherograms of the 5′ and 3′ DMPK sizing reactions of USN16349 (a), USN02610 (b) and 
USN24933 (c). In USN16349 the normal allele of 34 repeats was not visible and this sample was incorrectly 
interpreted to have a normal allele of 5 CTG repeats. The electropherogram of a random sample with a normal 
allele of 5 CTG repeats next to an expanded allele, USN02610, however, shows a different profile. The peak after 
the CTG repeat of 5 drops much stronger in USN02610 compared to USN16349. A normal allele of 29 next to 
an expanded allele, as in USN24933, is correctly identified.
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To complete the assessment of the performance of the DMPK sizing kit 235 clinical samples were tested. All 
normal alleles regardless of the genotype (in total 332 alleles) were detected within 1 repeat of the references 
with one exception. In this case (USN16349) the CTG repeat length was incorrectly sized using the DMPK sizing 
kit as 5 CTG repeats instead of 34. This was the largest normal allele tested in a sample that also has a CTG(>150) 
allele. The second largest normal allele of 29 CTG repeats on one allele next to a pathogenic expansion on the 
other allele was correctly identified. In retrospect, the electropherogram of USN16349 is also not indicative for 
Figure 2. Electropherogram of the 5′ DMPK sizing reaction of USN07618. USN07618 was previously 
determined to have a repeat-interruption. The results of the DMPK sizing kit are indicative of the presence of an 
interruption, as gaps are present in the ladder/tooth-comb pattern since the (CAG)n primer cannot anneal at the 
interruption.
Unique Study Number Expected No. of repeats Reaction
No. of CTG and non-CTG Repeats
Sizing Kit Reference
Allele 1 Allele 2*
5′-[CTGn-(XXXn)-
CTGn]-3′† Interruption pattern/Remarks
USN03117 12; >150 5′ 12 229 ND
3′ 12 199 ND
USN04034 12; >150 5′ 12 225 ND
3′ 12 114 [39-(63)-12] (CTG)n(CCGCTG)~100(CTG)n
USN08692 13; >150 5′ 13 240 ND
3′ 13 210 [147-(3)-6-(34)-20] (CTG)n(CCGCTG)114(CTG)n
USN00144 5; 174 5′ 5 154 [10-(2)-6-(79)-57]
3′ 5 146 [10-(2)-6-(73)-54] (CTG)24(CCGCTG)45(CTG)60
USN01084 13; >150 5′ 13 94–105 ND
3′ 13 78 ND (CTG)n(CCGCTG)167(CTG)n
USN01299 13; >150 5′ 13 259 [193-(50)-16]
3′ 13 190 [118-(4)-6-(49)-13] (CTG)n(CCGCTG)37(CTG)n
USN06424 5; >150 5′ 5 253 ND
3′ 5 161 [80-(43)-38]
USN07618 14; >150 5′ 14 205 [26-(2)-8-(55)-113]
3′ 14 105–135 ND
Table 3. Detection of non-CTG repeat interruption using the DMPK Sizing kit on eight samples with aberrant 
initial results. *The number of repeats was based on the presence of peaks (the approximation approach) and for 
large expanded alleles was the actual count until peaks diminished without applying the cut-off to facilitate the 
analysis of non-CTG repeats. †ND: No detection of interruptions.
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a repeat length of 5 (Fig. 1). It is anticipated that such aberrant patterns will be identified when the operators 
will become more familiar with the kit. More importantly, this sample was categorized into the correct genotype 
group of [CTG(5–35); CTG(>150)], as the expanded allele was detected. Of the 140 alleles with a repeat length above 
35, 5 differed by more than 5 repeats from the original determined length. Southern blot analyses of these 5 cases 
showed that the length of >180 determined by the DMPK sizing kit was most likely correct. The improvement 
of the DMPK sizing kit over the original tests in these samples is most likely due to the improved identification 
of longer repeats lengths (up to around 230–250 repeats), whereas the reference approach relied on a PCR that 
has a sizing limit of approximately 125–150 repeats7. Somatic heterogeneity of CTG repeat length is a common 
feature in blood cells of myotonic dystrophy patients18 and Southern blot analysis of these samples showed indeed 
somatic heterogeneity. The incorrect sizing by the historical test is most likely due to the preferential amplification 
of the shorter expanded alleles by the PCR of the reference method. Ultimately, the DMPK sizing kit classified all 
the clinical samples accurately into the respective allelic classes and yielded an overall performance of 100% in 
both sensitivity and specificity.
As the CTG repeat in DMPK can increase significantly upon transmission to off-spring thereby possibly caus-
ing a fatal congenital disease, prenatal testing is often requested for DM119. The 235 clinical samples consisted 
of 10 prenatal samples derived from amniotic cells or chorionic villus with repeat length in the genotypes of 
CTG(5–35) and CTG(>150). In all prenatal samples the CTG repeat length was correctly determined.
Interruptions of the normally pure CTG repeat in the DMPK gene have been described in 3–5% of expanded 
alleles12–14. Due to the nature of the interruptions, CTG/CAG primers in the TP-PCR will not anneal to the inter-
rupted regions and higher G/C content may also compromise PCR and result in allelic dropouts. In six out of 
eight samples with previously identified interruptions, repeat expansions with interruptions were easily detected 
using the DMPK sizing kit, due to gaps in the electropherogram patterns. In the additional two samples there 
was a clear indication of the presence of an interruption due to the difference of more than 5 repeats between 
the 5′ and 3′ reaction. Unlike the pathogenic expansions without interruptions, differences between the 5′ and 3′ 
reactions were well above 5 repeats in the interrupted pathogenic expansions. The large differences in sizes are 
likely due to the non-CTG repeat tracts impairing the identification of the complete repeat in either or both the 5′ 
and/or 3′ reactions. An interrupted expansion may be sized inaccurately by TP-PCR if the interruption extends 
beyond the detection limit of the TP-PCR at both ends of the expanded tract15. Case USN01084 fits the above 
description, as a continuous electropherogram pattern was present in both the 5′ and 3′ reactions, suggestive of a 
CTG repeat size of 94–105 or 78, respectively. Nevertheless, the difference in repeat length between the 5′ and the 
3′ reactions was noticeably larger than what could be attributed solely to variations of assays in design, suggestive 
of an interruption located in the approximate middle of the repeat. Thus, when the CTG repeat length determined 
by the 5′ and 3′ reaction deviates by more than five repeats, most likely an interrupted repeat is present and addi-
tional tests (such as Southern blotting) should be performed to characterize the repeat length. However, if the 
repeat length is determine to be >150 by one or both the 5′ and 3′ reactions, the repeat should be assigned as an 
unstable pathogenic allele and further characterization will have no clinical consequence.
Four of the interrupted CTG(>150) repeats with aberrant electropherogram patterns were previously charac-
terized by enzyme digestion and Southern blot. These results deviated from the results determined by the DMPK 
sizing kit in number and location of the interruptions. One obvious reason for the difference is that the reference 
approach was more specific with types of sequences recognized by the restriction enzyme, whereas primer bind-
ing in TP-PCR is affected by any repeat interruption. Long-read sequencing may determine the exact sequence 
of these interrupted alleles in the future. Initial studies on limited numbers of patients have suggested that inter-
rupted repeat expansions are more stable and DM1 patients with interrupted repeat expansions have a later dis-
ease onset compared to DM1 patient with pure CTG repeat expansions of the same length13,14,20,21. However, 
the poor individual correlation between repeat length and disease severity and the large heterogeneity in type, 
location and length of repeat interruptions makes studies on large groups of DM1 patients with interrupted 
repeats necessary to determine whether it is of prognostic value to determine if an expansion is interrupted and/
or quantify the CTG and non-CTG repeat tracts of the interrupted expansions.
In conclusion, the FastDM1TM DMPK sizing kit was found to be robust and accurate. The analytical sensitivity 
was not altered when the DNA input was varied to as low as a quarter or as high as twice the recommended amount. 
Similarly, the analytic specificity maintained well without generating any non-specific profiles even when DNA con-
taining a non-DMPK CTG repeat expansion was introduced into the testing. The consistency of the kit was estab-
lished as <0.41% CV for intra-assay, intra-batch and inter-batch variations. These parameters suggested that the kit 
performances will easily be obtainable at the user’s ends. The kit addressed the specific testing need for accurately 
categorizing samples into the respective genotypes (i.e. to clearly distinguish between repeats under and over 150 
repeats). Moreover in 5 samples the kit correctly identified the unstable pathogenic allele (CTG(>150)), while a previ-
ously performed TP-PCR test incorrectly determined the presence of an unstable intermediate allele (CTG(50–150)). 
Hence the FastDM1TM DMPK sizing kit represents an attractive alternative to current approaches in DM1 testing.
Methods
Reference DNA samples. Twenty-three reference samples of cell line-derived DNA from Coriell Cell 
Repositories (Camden, USA) were included in this study. Sizing accuracy was examined using 19 well character-
ized samples with sizing information and/or common consensus reported elsewhere16 (Supplementary Table S1). 
To examine the analytic sensitivity and specificity of the kit, four reference samples covering CTG repeats of dif-
ferent lengths from normal to large expanded alleles (NA03928, NA06075, NA23378 and NA04567) were selected. 
The analytic sensitivity of the kit was established using the four samples in varying amounts of DNA inputs at 
1, 5, 10, 25, 50, 100 and 200 ng per reaction. The analytic specificity was evaluated using the same four samples 
(NA03928, NA06075, NA23378 and NA04567) with the introduction of another reference sample (NA20232) 
with a CTG repeat expansion in another gene. To evaluate the sensitivity of the kit in detecting low level mosaicism 
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of expanded alleles, four series of mixtures were created using eight samples (NA16243/NA23258, NA03928/
NA05152, NA23265/NA04033 and NA23378/NA23299) to simulate mosaic content. These samples were mixed in 
various proportions, yet maintained a total DNA input of 100 ng per reaction. The resulting simulated mosaic sam-
ples contained 1%, 2.5%, 5%, 10%, 20%, 50% and 100% of the allele with the longest repeat length. All samples were 
additionally checked for their quantity and purity using common practices. DNA concentration was estimated by 
absorbance of 260 nm whereas the purity evaluated by calculating the ratio of A260/A280.
DNA Samples from clinical archive. The clinical performance of the sizing kit was validated using 235 
archived clinical samples from the Radboud University Medical Center, which were anonymized and coded with 
an unique study number (USN). These consisted of 225 postnatal samples, source material whole blood (n = 224) 
or cord blood (n = 1) and 10 prenatal samples, source material amniotic cells (n = 5) or chorionic villus (n = 5). 
Furthermore, eight additional samples were tested with initial testing results indicative for the presence of inter-
rupted repeat expansions. DNA was isolated using the fully automated Chemagic Star according to manufactur-
er’s recommendations (Perkin Elmer, Waltham, USA). The samples were characterised at Radboud University 
Nijmegen Medical Center for DMPK CTG repeat length using a combination of methods including conven-
tional PCR, TP-PCR and/or Southern blot of long-range PCR products7. Five samples were additionally tested 
using Southern blot of long-range PCR products, digested with restriction enzyme (Aci I and MspA 1I; Prof D. 
Monckton unpublished data). Usage of archived DNA samples for validation purpose was permitted under the 
guidelines of the Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
FastDM1tM DMpK sizing kit. The FastDM1TM DMPK sizing kits (labelled “For Research Use Only” (RUO)) 
were obtained from The BioFactory Pte Ltd (Singapore, Singapore). The kit was developed based on previous studies 
by Lian et al.10,22. It utilizes a triplet-primed polymerase chain reaction, which includes a combination of primers 
targeting a flanking region as well as five CTG repeats. A schematic figure of the reaction is shown in Supplementary 
Fig. S1. Primer mixes were designed to amplify from the 5′ and 3′ ends of the DMPK CTG repeat region.
The TP-PCR assays of the kit were performed according to manufacturer’s instructions in 15 μL volumes with 
100 ng of genomic DNA per test, unless otherwise stated. The 5′ and 3′ TP-PCR reactions were carried out in 
separate tubes using a Bio-Rad C1000 (Bio-Rad, Hercules, USA) or Veriti (Applied Biosystems, Foster City, USA) 
thermal cycler. The TP-PCR comprised of an initial denaturation step at 95 °C for 15 min followed by 35 cycles of 
98 °C for 45 sec, 60 °C for 45 sec and 72 °C for 5 min, with a final extension step at 72 °C for 10 min.
TP-PCR amplification products were analysed by capillary electrophoresis (CE). Briefly, a 2 µL aliquot of each 
amplicon was mixed with 0.5 µL of MapMarker®1000-ROX (Bioventures Inc, Murfreesboro, USA) or GeneScan™ 
1200 LIZ™ (Applied Biosystems) size standard and 9 µL of Hi-Di™ formamide (Applied Biosystems). The mix-
ture was denatured at 95 °C for 5 min. The mixture was analyzed on an ABI 3730xL DNA Analyzer (Applied 
Biosystems) with a capillary length of 50 cm and running POP-7 polymer. CE settings were an injection time of 
5 sec at 3 kV or 1 kV for LIZ™ and capillary electrophoresis for 50 min at 15 kV.
Data analysis and result interpretation. Electropherograms were analysed with Peakscanner software 
(version 2.0, Applied Biosystems) or Genemarker software (version 2.6.7, SoftGenetics, State College, USA), fol-
lowing manufacturer’s instructions. Briefly, the electropherograms were visually checked for aberrant results (e.g. 
contamination in the no template controls, or incorrect calling of size standard peaks) and valid electrophero-
grams were subjected to repeat sizing analysis. The final peak of each sample was identified based on signal height 
and/or peak morphology. The repeat size was determined by counting the first until the respective final peak(s) 
or by approximation based on correction factor calculated using distance between the two peaks in base pairs. In 
this way, the amount of CTG repeats was determined ranging from 5 till 180, and repeats longer than 180 were 
classified as >180. Samples for the clinical performance testing were classified into the respective genotypes (i.e. 
CTG(5–35), CTG(36–50), CTG(51–150) and CTG(>150)) based on the reported repeat size of the largest allele, following 
the EMQN guidelines7. Of note, 95% confidence intervals of specificity and sensitivity were calculated using 
Wilson score interval. Coefficient of variation (CV) was used for the study of consistency and was measured by 
the ratio of the standard deviations (SD) to the mean (SDs over the averages of the respective sets of data points). 
Furthermore, aberrant patterns or significant disagreements between the 5′ and 3′ TP-PCR reaction samples were 
interpreted as indicative of “non-CTG repeat” interruptions or rare deletion on one end of the CTG repeat region. 
For the study of “non-CTG repeat” interruptions, repeats of large expanded alleles were counted until peak sig-
nal diminished without applying the cut-off (i.e. carry on counting beyond 180 repeats). The size of “non-CTG 
repeats” was calculated based on the absence of peaks using the difference in base pairs between the adjacent 
peaks. Example electropherograms of pure CTG and interrupted CTG repeats of the 5′ and 3′ DMPK sizing reac-
tion of clinical samples with different repeat lengths are shown in Supplementary Fig. S3.
Data analysis was performed blinded by a technician and clinical laboratory geneticist in training. Their 
results were compared to each other and when the results did not match the sample was re-examined until a joint 
agreement was reached. Only then were results compared to the results of the original test.
Data Availability
The datasets generated and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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